To those responsible for what happened to my sister, Amy Bradley:
1. Her case is unsolved, but it is not unsolvable.
2. The future has a way of catching up with the past.
3. Time does not erase the truth. It only changes who is willing to reveal it.
#AmyBradley
BREAKING: Largest Human Cancer Study of Ivermectin + Mebendazole Is Now PEER-REVIEWED and PUBLISHED in a MAJOR Cancer Journal
84.4% of cancer patients taking ivermectin + mebendazole for 6 months declared either CANCER DISAPPEARANCE, TUMOR REGRESSION, or CANCER STABILIZATION.
Our study, “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” is now peer-reviewed and published in Anticancer Research—a major international oncology journal of the International Institute of Anticancer Research (IIAR), established in 1995.
The results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.
A diverse population of cancer patients (n=197) was prescribed compounded ivermectin–mebendazole through a U.S. telemedicine platform, with each capsule containing 25 mg ivermectin and 250 mg mebendazole.
Participants were followed for approximately six months using standardized digital surveys assessing cancer outcomes, medication adherence, and tolerability.
At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR)—meaning more than four out of five patients reported either:
No evidence of disease (32.8%)
Tumor regression (15.6%)
or Cancer stabilization (36.1%)
Importantly, adherence was remarkably high, with 86.9% completing the initial prescription and 66.4% remaining on therapy at six months.
Side effects were predominantly mild and manageable, reported in 25.4% of patients (primarily gastrointestinal), with 93.6% of those experiencing side effects continuing treatment after minor dosing adjustments.
This groundbreaking peer-reviewed publication was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel—uniting real-world clinical data, frontline medical experience, and epidemiologic expertise to evaluate inexpensive, repurposed therapies with major translational potential.
With these extraordinarily promising results, double-blind, placebo-controlled clinical trials are now required.
In the meantime, many cancer patients are exercising their right to try.
@twc_health@McCulloughFund@IIAR_Journals@P_McCulloughMD@DrHarveyRisch@DrKellyVictory@jathorpmfm@drdrew@PeterGillooly@FosterCoulson
I hate Spring time in Ireland. I’ve got a hot water bottle at my feet, AND a fan pointed straight at me. How can a place be simultaneously hot and cold 🙃
Love is Blind Poland is by far the worst season ever made.
What were they thinking?! Ooh yes, lets make a series about emotions, in the, famously, most emotion-less place in the world... Genius!
#LoveIsBlind#LoveIsBlindPoland#LoveIsBlindPolska
@Gagamonster1189 I love Poland, don’t get me wrong. The people are beautiful, and especially their blue eyes sparkled on the screen!
Just not sure it’s ideal for the format exactly
@Gagamonster1189 I agree with you, but it was like drawing blood from a stone!
Anytime there was conflict in the pods, the participants just walked out, avoiding any communication… this season must have set a record for the amount of pod walk-outs!
#LoveIsBlind#LoveIsBlindPoland
@BradRad5Bradley Hi Brad, just to to let you know, not sure if you’ve seen this yet. Khloe Kardashian discussing Amy on her podcast released today. It’s at mark 21:19
I have not listened to it yet, just wanted to make sure you saw it as soon as possible 👍🏻
https://t.co/OSv9HWx2l4
Witness Wednesday this week on Midnight Mystery Archive highlights a conversation with Amy’s boyfriend at the time of her disappearance, Tom.
https://t.co/UCFwnMeNsy